Renaissance Technologies LLC Increases Stake in CryoPort, Inc. $CYRX

Key Points

• Renaissance Technologies increased its CryoPort stake by 62.9% in the first quarter to 368,110 shares, while institutional investors collectively own 92.9% of the company.
• CryoPort reported second-quarter revenue of approximately $49.0 million, up 8% year over year and above estimates, but its adjusted EPS loss of $0.20 narrowly missed expectations.
• Analyst sentiment remains favorable, with seven Buy ratings and two Holds producing a “Moderate Buy” consensus and an average price target of $18; however, insiders sold $3.6 million of shares over the past three months.

Renaissance Technologies LLC raised its holdings in shares of CryoPort, Inc. (NASDAQ:CYRX - Free Report) by 62.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 368,110 shares of the company's stock after acquiring an additional 142,070 shares during the quarter. Renaissance Technologies LLC owned approximately 0.73% of CryoPort worth $3,048,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of CYRX. State of Wyoming increased its position in CryoPort by 9.4% in the first quarter. State of Wyoming now owns 42,520 shares of the company's stock worth $352,000 after buying an additional 3,638 shares in the last quarter. Penbrook Management LLC raised its stake in CryoPort by 251.6% during the 1st quarter. Penbrook Management LLC now owns 185,775 shares of the company's stock worth $1,538,000 after acquiring an additional 132,940 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of CryoPort by 0.6% in the first quarter. Assenagon Asset Management S.A. now owns 1,495,683 shares of the company's stock worth $12,384,000 after purchasing an additional 8,280 shares during the period. Corient Private Wealth LLC bought a new position in shares of CryoPort in the fourth quarter worth approximately $113,000. Finally, Invesco Ltd. raised its position in shares of CryoPort by 19.3% during the 4th quarter. Invesco Ltd. now owns 96,541 shares of the company's stock valued at $927,000 after purchasing an additional 15,607 shares during the period. 92.90% of the stock is owned by institutional investors.

Key Stories Impacting CryoPort

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Needham raised its price target to $19 from $15 and reiterated a “buy” rating, implying substantial upside from recent trading levels. The upgrade reflects confidence in CryoPort’s growth outlook and pipeline exposure. Benzinga report
• Positive Sentiment: Second-quarter revenue increased 8% year over year to approximately $49.0 million. Life Sciences Services revenue rose 15%, while BioStorage/BioServices revenue grew 25%, showing accelerating demand in key businesses. CryoPort was supporting 779 clinical trials and 22 commercially approved cell and gene therapies at quarter-end. CryoPort second-quarter results
• Positive Sentiment: Investor confidence has improved alongside CryoPort’s expanding pipeline. Conestoga Capital Advisors highlighted the company in its second-quarter investor letter, providing additional institutional-investor support for the growth story. Investor confidence report
• Neutral Sentiment: Management’s fiscal 2026 revenue guidance of $192 million to $196 million brackets the analyst consensus of $194.2 million, signaling continued growth but no major near-term guidance surprise. Q2 2026 earnings call transcript
• Negative Sentiment: Adjusted quarterly EPS was a loss of $0.20, narrowly below the $0.19 loss expected by analysts. Although the loss improved from $0.29 per share a year earlier, the slight earnings miss and CryoPort’s negative return on equity remain concerns for investors. CryoPort Q2 earnings report

CryoPort Trading Up 2.8%

Shares of NASDAQ CYRX opened at $15.12 on Friday. CryoPort, Inc. has a 12-month low of $7.51 and a 12-month high of $16.89. The firm's 50-day moving average price is $15.49 and its 200-day moving average price is $11.92. The stock has a market capitalization of $762.05 million, a price-to-earnings ratio of -16.80 and a beta of 1.89.

CryoPort (NASDAQ:CYRX - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.01). The company had revenue of $48.97 million for the quarter, compared to analysts' expectations of $48.18 million. CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.13%. On average, equities analysts predict that CryoPort, Inc. will post -0.85 EPS for the current fiscal year.

Analyst Ratings Changes

CYRX has been the subject of several research analyst reports. BTIG Research increased their target price on CryoPort from $17.00 to $25.00 and gave the stock a "buy" rating in a research report on Friday, July 24th. Wall Street Zen raised shares of CryoPort from a "sell" rating to a "hold" rating in a report on Monday, May 11th. KeyCorp upped their target price on shares of CryoPort from $15.00 to $17.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 20th. Needham & Company LLC lifted their price target on shares of CryoPort from $15.00 to $19.00 and gave the company a "buy" rating in a report on Friday. Finally, Jefferies Financial Group set a $13.50 price objective on shares of CryoPort in a report on Monday, June 8th. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $18.00.

Insiders Place Their Bets

In other news, Director Ramkumar Mandalam sold 23,214 shares of the company's stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $15.44, for a total transaction of $358,424.16. Following the transaction, the director owned 67,894 shares of the company's stock, valued at approximately $1,048,283.36. This represents a 25.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Edward J. Zecchini sold 33,600 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $14.47, for a total value of $486,192.00. Following the completion of the sale, the insider owned 109,719 shares in the company, valued at approximately $1,587,633.93. The trade was a 23.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 227,641 shares of company stock valued at $3,622,515 over the last three months. 9.50% of the stock is owned by company insiders.

CryoPort Company Profile

CryoPort, Inc NASDAQ: CYRX is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort's product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.

Want to see what other hedge funds are holding CYRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoPort, Inc. (NASDAQ:CYRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source